MergerMay 29, 2026, 04:56 PM
Lisata Therapeutics Amends Merger Terms: Cash Offer $4.00, CVRs up to $3.00
AI Summary
Lisata Therapeutics, Inc. amended its merger agreement with Kuva Labs Inc., revising the offer price per common share. The cash component was reduced from $5.00 to $4.00 per share, while the contingent value right (CVR) potential increased from $1.00 to an aggregate of $3.00 per CVR, subject to two specified milestones. The first milestone payment of $1.25 is tied to the LSTA1-GBM-2A Phase 2a trial, and the second milestone payment of $1.75 is linked to the FDA NDA filing for certepetide. The tender offer commencement and outside dates were also extended.
Key Highlights
- Cash offer per common share reduced from $5.00 to $4.00.
- Contingent Value Right (CVR) potential increased from $1.00 to an aggregate of $3.00.
- First CVR milestone payment of $1.25 for LSTA1-GBM-2A Phase 2a trial enrollment/completion.
- Second CVR milestone payment of $1.75 for FDA NDA filing/acceptance of certepetide.
- Tender offer commencement date extended from May 29, 2026, to June 1, 2026.
- Merger Agreement's "Outside Date" extended from July 1, 2026, to July 6, 2026.
Price Impact
More from LSTA